Introduction
One of the most pressing challenges in ketamine therapeutics is the inability to predict which patients will respond to treatment before initiating therapy. While ketamine produces rapid antidepressant effects in approximately 50 to 70 percent of patients with treatment-resistant depression, the remaining 30 to 50 percent experience the costs, risks, and side effects of treatment without meaningful clinical benefit. The identification of reliable biomarkers that predict treatment response before or early in the course of ketamine therapy would represent a significant advance toward precision psychiatry, enabling clinicians to allocate this resource-intensive intervention to those patients most likely to benefit.
This article reviews the current evidence for candidate biomarkers across four domains: peripheral blood-based markers, neuroimaging signatures, genetic and pharmacogenomic factors, and electrophysiological features.
Blood-Based Biomarkers
Inflammatory Markers
The relationship between systemic inflammation and depression has generated substantial interest in inflammatory biomarkers as predictors of ketamine response. C-reactive protein (CRP), a widely available and inexpensive acute-phase reactant, has emerged as one of the most studied candidates.
Clinical: Preliminary evidence suggests that patients with baseline CRP levels above 1 mg/L may show greater antidepressant response to ketamine than those with lower inflammatory burden, although validation in large prospective studies is ongoing.
Machado-Vieira et al. (2017) reported that higher baseline levels of interleukin-6 (IL-6) predicted greater antidepressant response to a single ketamine infusion. Chen et al. (2018) found that the ratio of pro-inflammatory to anti-inflammatory cytokines before treatment was associated with the magnitude of mood improvement at 24 hours post-infusion. These findings align with the broader hypothesis that inflammation-driven depression represents a biologically distinct subtype that is particularly responsive to ketamine's combined anti-inflammatory and neurotrophic mechanisms.
However, inflammatory markers have significant limitations as standalone predictors. Peripheral cytokine levels are influenced by numerous confounders including body mass index, concurrent medications, time of day, and comorbid medical conditions. The sensitivity and specificity of any single inflammatory marker remain insufficient for individual-level clinical prediction.
Neurotrophic Markers
Brain-derived neurotrophic factor (BDNF) has been investigated as both a predictor of and a surrogate marker for ketamine response. Haile et al. (2014) found that higher baseline plasma BDNF levels predicted better antidepressant response to ketamine infusion. This finding is somewhat counterintuitive, as the neurotrophic hypothesis would suggest that patients with the lowest BDNF levels (and therefore the greatest neurotrophic deficit) should benefit most. One interpretation is that higher baseline BDNF reflects greater neuroplastic reserve, enabling a more robust synaptogenic response to ketamine-induced TrkB-mTOR pathway activation.
Post-treatment BDNF changes have shown inconsistent associations with clinical response across studies, partly because peripheral BDNF measurement is confounded by platelet storage and release dynamics that do not necessarily reflect central nervous system BDNF signaling.
Metabolic and Endocrine Markers
Emerging evidence implicates metabolic markers in ketamine response prediction. Insulin resistance, as measured by the homeostatic model assessment (HOMA-IR), has been associated with differential antidepressant response patterns. Preliminary data suggest that patients with features of metabolic syndrome may show distinct ketamine response trajectories, though the direction and reliability of this association require further study.
Cortisol dynamics, reflecting hypothalamic-pituitary-adrenal (HPA) axis function, have also been investigated. Patients with hypercortisolemia at baseline may respond differently to ketamine than those with normal cortisol regulation, though the clinical utility of cortisol-based prediction remains unestablished.
Neuroimaging Biomarkers
Structural MRI Findings
Structural brain differences have been explored as predictors of ketamine response. Abdallah et al. (2017) reported that greater baseline anterior cingulate cortex (ACC) volume was associated with better antidepressant response to ketamine. The ACC is a key node in the brain's salience and emotional regulation networks, and its structural integrity may reflect the capacity for ketamine-induced neuroplastic remodeling.
Hippocampal volume, a marker of cumulative stress-related neuronal atrophy, has also been studied. Smaller hippocampal volumes at baseline have been associated with greater response to ketamine in some studies, potentially because these patients have the most to gain from ketamine's synaptogenic effects.
Functional Connectivity Patterns
Resting-state functional MRI (rs-fMRI) studies have identified connectivity patterns that distinguish ketamine responders from non-responders. Default mode network (DMN) hyperconnectivity, which is associated with rumination and self-referential processing in depression, has been studied as a potential predictive feature. Patients with greater baseline DMN hyperconnectivity may show larger improvements following ketamine treatment, as ketamine is known to acutely disrupt DMN connectivity patterns.
Info: Functional connectivity between the anterior cingulate cortex and the posterior cingulate cortex, two key nodes of the default mode network, appears to be a particularly promising neuroimaging biomarker, though it requires specialized equipment and analysis pipelines not available in routine clinical practice.
Chen et al. (2019) used machine learning algorithms applied to resting-state fMRI data to predict ketamine response with approximately 80 percent accuracy in a small sample. While these results are encouraging, they require replication in larger, independent cohorts before clinical implementation can be considered.
PET Imaging
Positron emission tomography (PET) studies using mu-opioid receptor and glutamate receptor radioligands have provided mechanistic insights into ketamine response prediction. Patients with greater baseline mu-opioid receptor availability in the ACC showed larger antidepressant responses, suggesting that individual differences in endogenous opioid system tone may influence ketamine efficacy. PET imaging of microglial activation using TSPO ligands is also being explored as a way to identify patients with neuroinflammatory burden who may preferentially respond to ketamine's anti-inflammatory properties.
Genetic and Pharmacogenomic Markers
BDNF Val66Met Polymorphism
The BDNF Val66Met polymorphism (rs6265) was among the first genetic markers investigated in ketamine pharmacogenomics. The Met allele impairs activity-dependent BDNF secretion, which is a critical step in ketamine's mechanism of action. Early studies by Laje et al. (2012) suggested that Met allele carriers showed blunted response to ketamine, consistent with the mechanistic prediction. However, subsequent studies have produced conflicting results, with some finding no significant association and others reporting differential effects depending on ethnicity and concurrent medications.
Cytochrome P450 Metabolizer Status
Ketamine is primarily metabolized by CYP2B6 and CYP3A4 to norketamine and subsequently to hydroxynorketamine (HNK) metabolites. Genetic polymorphisms in these enzymes produce distinct metabolizer phenotypes (poor, intermediate, extensive, and ultra-rapid) that affect ketamine and metabolite plasma concentrations. Since (2R,6R)-HNK has been proposed as an active metabolite contributing to antidepressant efficacy through mechanisms independent of NMDA receptor blockade, CYP2B6 metabolizer status could theoretically influence treatment response by altering the ratio of parent drug to active metabolite.
Preliminary pharmacogenomic studies suggest that CYP2B6 slow metabolizers may achieve higher ketamine and lower HNK levels, potentially producing different efficacy and side effect profiles compared to extensive metabolizers. However, prospective clinical studies linking CYP2B6 genotype to treatment outcomes are limited.
Glutamate System Genes
Polymorphisms in genes encoding NMDA receptor subunits (GRIN2A, GRIN2B), AMPA receptor subunits (GRIA1), and the glutamate transporter (SLC1A2) have been investigated as candidates for pharmacogenomic prediction. A GRIN2B polymorphism (rs1805502) was associated with differential ketamine response in a study by Niciu et al. (2014), though replication has been limited. Genome-wide association studies (GWAS) specifically designed for ketamine pharmacogenomics are needed but have not yet been completed due to the relatively small sample sizes available.
Electrophysiological Biomarkers
EEG-Based Prediction
Electroencephalography (EEG) offers a practical, scalable approach to biomarker assessment that could be implemented in routine clinical settings. Several EEG features have shown promise as ketamine response predictors.
Baseline theta-band power over frontal electrodes, reflecting anterior cingulate cortex activity, has been associated with subsequent treatment response. Patients with greater pre-treatment frontal theta activity showed larger antidepressant responses to ketamine in studies by Cornwell et al. (2012) and Nugent et al. (2019). Gamma-band oscillation changes during ketamine infusion have also been investigated as early response markers.
Sleep EEG parameters, particularly slow-wave activity during non-rapid eye movement sleep, have been explored as both predictors and early markers of ketamine response. Ketamine's effects on sleep architecture, including enhancement of slow-wave sleep in some studies, may reflect synaptic potentiation processes that correlate with clinical improvement.
Loudness Dependence of Auditory Evoked Potentials
The loudness dependence of auditory evoked potentials (LDAEP), an electrophysiological measure reflecting central serotonergic tone, has been investigated as a predictor of antidepressant response across medication classes. Preliminary data suggest that LDAEP may also predict ketamine response, though the evidence base is limited to small studies requiring replication.
Toward Multi-Marker Prediction Models
The most promising direction in ketamine biomarker research involves combining multiple markers into integrated prediction models. No single biomarker has achieved sufficient predictive performance for clinical use, but multi-modal approaches incorporating inflammatory markers, clinical features (depression severity, number of failed medication trials, anxiety comorbidity), genetic data, and neuroimaging or EEG features may achieve clinically meaningful prediction accuracy.
Machine learning methods, including support vector machines and random forest algorithms, have been applied to multi-dimensional datasets with encouraging preliminary results. Prospective validation of these models in independent clinical populations represents the critical next step before biomarker-guided treatment selection can be recommended for routine clinical practice.
References
- PubMed: Biomarkers of Ketamine's Antidepressant Effect: A Systematic Review — Systematic review of candidate biomarkers for predicting and monitoring ketamine antidepressant response
- PubMed: Neural Predictors of Treatment Response to Ketamine — Review of neuroimaging and electrophysiological predictors of ketamine efficacy in depression
- PubMed: Pharmacogenomics of Ketamine: A Systematic Review — Systematic review of genetic factors influencing ketamine metabolism and clinical response
- NIMH: Depression Overview — National Institute of Mental Health information on depression and precision treatment approaches
- NIH: Precision Medicine Initiative — National Institutes of Health program advancing biomarker-guided individualized treatment
Share